Monday, May 19th, 2014
11:00am – 12:00pm (EST)
Presenter: Albert J. Giovenella, Ph.D.
In the past few years, a number of large pharmaceutical companies have sizably-reduced their R&D staffs while in the process of updating their business models. This has been an adjustment to greater licensing and outsourcing to find new compounds as the need has arisen to quickly fill their pipelines with promising assets. The latter has been an alternative to long and laborious efforts that are needed in pharmaceutical development.
There are some concepts to think about that might ease the pressure on this current situation, in which so many R&D employees have been turned out.
These concepts, which will be explained in this presentation might be: (1) making an earlier “go-no go” decision in the discovery and development process, (2) putting more resources in the Phase III part of the process, since more certain assets and more work, including outcomes studies would be characterizing this portion of development, (3) sticking to a steady in house-outsourcing ratio over a log period of time to stabilize important resources, and (4) training young entrepreneurs how to integrate scientific knowledge into key biotech business decision-making.
Accurate decision-making should be heavily based on scientific principles in the early part of the R&D process, and scientific-based decision making should be stressed in the education of young scientists.
Finally, keeping a large mechanism-based historic data set in each therapeutic area would construct a strong base to consult in starting difficult long-term scientific decisions for the future.
Albert J. Giovenella, Ph.D.
Adjunct Assistant Professor of Medicine
University of Pennsylvania School of Medicine
Moderator: Dawn Van Dam
President and CEO
One Million Solutions in Health